These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26758422)

  • 61. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
    J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.
    Amengual JE; Clark-Garvey S; Kalac M; Scotto L; Marchi E; Neylon E; Johannet P; Wei Y; Zain J; O'Connor OA
    Blood; 2013 Sep; 122(12):2104-13. PubMed ID: 23913470
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
    Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
    Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
    Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
    Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Beleodaq approved for rare lymphomas.
    Cancer Discov; 2014 Sep; 4(9):978. PubMed ID: 25185167
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
    Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
    Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.
    Agarwal N; McPherson JP; Bailey H; Gupta S; Werner TL; Reddy G; Bhat G; Bailey EB; Sharma S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):299-308. PubMed ID: 26719074
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
    Duvic M
    Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
    Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
    Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
    Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
    J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
    Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
    Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.
    Reimer P; Chawla S
    J Hematol Oncol; 2013 Sep; 6():69. PubMed ID: 24020452
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Histone deacetylase inhibitors: Are they here to stay?
    Ibrahim RB
    Am J Health Syst Pharm; 2010 May; 67(10):791. PubMed ID: 20479099
    [No Abstract]   [Full Text] [Related]  

  • 76. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
    Lassen U; Molife LR; Sorensen M; Engelholm SA; Vidal L; Sinha R; Penson RT; Buhl-Jensen P; Crowley E; Tjornelund J; Knoblauch P; de Bono JS
    Br J Cancer; 2010 Jun; 103(1):12-7. PubMed ID: 20588278
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
    Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
    Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
    Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).
    Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Buhl-Jensen P; Molife R; Brown R; de Bono JS; Evans TR
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1273-9. PubMed ID: 20706839
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
    Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
    J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.